SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IMMULOGIC
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Harold Engstrom who wrote (52)10/7/1996 5:19:00 PM
From: Paul Getman   of 305
 
There is one important news item that may well come before the pivotal phase III trial data on Allervax Cat and Ragweed--the announcement of a new partner to replace HMR. IMUL has promised that it would secure a partner within one year of HMR's decision to terminate the relationship. That would be by March 1997. However, Wall Street is putting lots of pressure on IMUL to announce something significant before year end. At a recent analyst meeting I attended, several analysts criticized IMUL management (in what was otherwise a friendly meeting) for not appreciating how strong a signal a new partnership would send to the investment community about IMUL's technology.

Depending on who the partner was, the territory covered (IMUL has said that it may want different partners for different parts of the world), the royalty arrangement (if revealed), the stock could perk up significantly on the announcement.

Paul
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News